Literature DB >> 26828748

Predictive value of Galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study.

Anna Lisowska1, Małgorzata Knapp2, Agnieszka Tycińska2, Elżbieta Motybel3, Karol Kamiński2, Przemysław Święcki2, Włodzimierz J Musiał2, Violetta Dymicka-Piekarska3.   

Abstract

OBJECTIVE: The role of Galectin-3(Gal-3) in atherosclerosis progression has not been definitely acknowledged. The aim of the study was to establish the following: whether Gal-3 may act as an independent risk factor of coronary artery disease (CAD) occurrence and its advancement, if Gal-3 has potential relations with classical and new markers of cardiovascular risk (carotid intima-media thickness (cIMT), and whether Gal-3 may be a marker of mortality in the group of patients with myocardial infarction (MI) during mid-term follow-up. PATIENTS AND METHODS: The study group was composed of 233 patients with MI and 100 patients with a stable CAD. Selected risk factors were assessed, Gal-3 concentrations and cIMT were measured. The control group was composed of 100 healthy individuals.
RESULTS: In the study group (MI and CAD patients) Gal-3 concentration was significantly higher than in the controls--median 7.9 ng/ml (p = 0.0001) and 10.7 ng/ml (p = 0.00001) vs. 5.5 ng/ml, respectively. Patients with 3-vessel disease had higher levels of Gal-3 than patients with 1-or 2-vessel disease (9.2 ng/ml vs 7.4 ng/ml, p = 0.003). In the group of MI patients who died during the follow-up (average period - 2.8 years), we found a significantly higher concentration of Gal-3 (20.0 ng/ml vs 8.0 ng/ml, p = 0.0005) and cIMT values (common carotid artery(CCA): 1.4 ± 0.4 mm vs. 1.0 ± 0.3 mm, p = 0.03; carotid bulb(CB): 2.3 ± 0.5 mm vs. 1.9 ± 0.4 mm, p = 0.009). In the model of multivariate logistic regression analysis, the variables influencing the mortality after MI during follow-up were: age>65 years, Gal-3 concentration>8.7 ng/ml, IMT values and plaque occurrence in CB, previous MI and EF<40%.
CONCLUSIONS: Gal-3 is an independent risk factor of CAD occurrence, but cIMT values are better markers of CAD advancement. Both Gal-3 concentration>8.7 ng/ml and IMT values in CB were an independent predictive indicators of increased risk of all-cause mortality in patients after MI during mid-term follow up.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Acute coronary syndromes; Galectin-3; Intima-media thickness; Stable coronary artery disease

Mesh:

Substances:

Year:  2016        PMID: 26828748     DOI: 10.1016/j.atherosclerosis.2016.01.022

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  13 in total

1.  Plasma Galectin-3 and Sonographic Measures of Carotid Atherosclerosis in the Atherosclerosis Risk in Communities Study.

Authors:  Abayomi Oyenuga; Aaron R Folsom; Oluwaseun Fashanu; David Aguilar; Christie M Ballantyne
Journal:  Angiology       Date:  2018-06-07       Impact factor: 3.619

2.  Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study.

Authors:  Rabea Asleh; Maurice Enriquez-Sarano; Allan S Jaffe; Sheila M Manemann; Susan A Weston; Ruoxiang Jiang; Véronique L Roger
Journal:  J Am Coll Cardiol       Date:  2019-05-14       Impact factor: 24.094

3.  Association of galectin-3 with markers of myocardial function, atherosclerosis, and vascular fibrosis in patients with rheumatoid arthritis.

Authors:  Panagiota Anyfanti; Eugenia Gkaliagkousi; Eleni Gavriilaki; Areti Triantafyllou; Panagiotis Dolgyras; Vasiliki Galanopoulou; Spyros Aslanidis; Stella Douma
Journal:  Clin Cardiol       Date:  2018-11-27       Impact factor: 2.882

Review 4.  Novel biomarkers for cardiovascular risk prediction.

Authors:  Juan Wang; Guo-Juan Tan; Li-Na Han; Yong-Yi Bai; Miao He; Hong-Bin Liu
Journal:  J Geriatr Cardiol       Date:  2017-02       Impact factor: 3.327

Review 5.  Correlation between Galectin-3 and Adverse Outcomes in Myocardial Infarction Patients: A Meta-Analysis.

Authors:  Lei Tian; Kan Chen; Zhihua Han
Journal:  Cardiol Res Pract       Date:  2020-05-07       Impact factor: 1.866

Review 6.  Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction-Promises and Challenges.

Authors:  Ioan Tilea; Andreea Varga; Razvan Constantin Serban
Journal:  Diagnostics (Basel)       Date:  2021-05-15

7.  Galectin-3 Identifies a Subset of Macrophages With a Potential Beneficial Role in Atherosclerosis.

Authors:  Karina Di Gregoli; Michelle Somerville; Rosaria Bianco; Anita C Thomas; Aleksandra Frankow; Andrew C Newby; Sarah J George; Christopher L Jackson; Jason L Johnson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-16       Impact factor: 8.311

Review 8.  Galectin-3 Is a Potential Mediator for Atherosclerosis.

Authors:  Ziyu Gao; Zhongni Liu; Rui Wang; Yinghong Zheng; Hong Li; Liming Yang
Journal:  J Immunol Res       Date:  2020-02-14       Impact factor: 4.818

9.  Combining Pulse Wave Velocity With Galectin-3 to Predict Mortality and Cerebrovascular and Cardiovascular Events in Hemodialysis Patients.

Authors:  Qi Zhang; Kanhua Yin; Mingli Zhu; Xinghui Lin; Yan Fang; Jiayue Lu; Zhenyuan Li; Zhaohui Ni
Journal:  Front Med (Lausanne)       Date:  2020-10-20

10.  Galectin-3 is related to right ventricular dysfunction in heart failure patients with reduced ejection fraction and may affect exercise capacity.

Authors:  Beata Zaborska; Grażyna Sygitowicz; Krzysztof Smarż; Ewa Pilichowska-Paszkiet; Andrzej Budaj
Journal:  Sci Rep       Date:  2020-10-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.